Unveiling the Financial and Strategic Dynamics of Catalent Inc's Market Position
The contract drug manufacturer was expected to file the report on Aug. 29. The company is awaiting the closing of the $16.5 billion takeover deal signed in February by Novo Holdings, the investment firm that has a controlling interest in Danish drugmaker Novo Nordisk. Catalent expects the deal to close towards the end of the year.
CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.